Human Albumin Biotest (Human Serum Albumin)

Human Albumin Biotest is indicated for clinical conditions where plasma volume expansion or correction of low albumin levels is needed.

• Hypovolemia due to severe burns, trauma, or major surgery.
• Cardiogenic or distributive shock where fluid resuscitation is required.
• Hypoalbuminemia associated with chronic liver disease, nephrotic syndrome, or protein‑losing enteropathies.
• Plasma volume expansion during cardiopulmonary bypass or extracorporeal circulation.
• Adjunct therapy in patients with severe sepsis or septic shock when albumin levels are markedly reduced.

• Human Albumin Biotest provides exogenous albumin, the most abundant plasma protein, which contributes to oncotic pressure. By increasing colloid osmotic pressure within the vascular compartment, it draws water from the interstitial space into the circulation, thereby expanding intravascular volume. The added albumin also serves as a carrier for endogenous substances such as hormones, fatty acids, and drugs, supporting physiological transport and distribution.

Adverse reactions to Human Albumin Biotest are generally related to the infusion process or to immune-mediated responses.

Common

• Transient fever, chills, or flushing during infusion.
• Mild hypotension or hypertension.
• Headache or dizziness.
• Nausea or mild gastrointestinal discomfort.
• Local irritation at the infusion site.

Serious

• Anaphylactic or severe allergic reactions, including urticaria and bronchospasm.
• Volume overload leading to pulmonary edema or heart failure.
• Hemolysis or renal impairment in susceptible patients.
• Transmission‑related infections (theoretical risk from plasma-derived products).
• Coagulopathy or bleeding tendency due to dilutional effects.
• Severe hypotension requiring vasopressor support.

Before administering Human Albumin Biotest, clinicians should evaluate patient history and monitor specific clinical parameters to minimize risk.

• Assess for known hypersensitivity to albumin or any plasma protein.
• Evaluate cardiac function; avoid use in patients with uncontrolled heart failure or severe fluid overload.
• Monitor fluid balance, blood pressure, and central venous pressure during and after infusion.
• Use caution in patients with renal impairment or active bleeding disorders.
• Adjust dose in patients with severe hypoalbuminemia or altered oncotic pressure.
• Consider pregnancy and lactation status; limited safety data are available.
• Ensure appropriate storage and handling to maintain product integrity.

Human Albumin Biotest may affect the pharmacokinetics of concomitant drugs or interact with other volume expanders.

Avoid

• Concurrent administration of other synthetic colloids (e.g., hydroxyethyl starch) that may increase risk of renal dysfunction.
• Simultaneous use of high‑dose diuretics without careful volume monitoring.

Use with caution

• Vasopressor agents; albumin infusion can potentiate blood pressure changes.
• Anticoagulants (heparin, warfarin); altered plasma volume may affect coagulation monitoring.
• Nephrotoxic drugs (aminoglycosides, NSAIDs); volume status influences renal clearance.
• Immunosuppressive therapies; potential for altered drug distribution.